Daiichi Sankyo's Class 1 New Drug DS-7011a Granted IND Approval in China for Systemic Lupus Erythematosus

Intelligent Finance APP learned that the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration disclosed that DS-7011a, a Class 1 new drug applied by Daiichi Sankyo (DSKYF.US), has been approved for clinical trials and is proposed to be developed for the treatment of Systemic Lupus Erythematosus (SLE). Public information shows that DS-7011a is an antagonistic antibody targeting TLR7, currently undergoing Phase 1b/2 clinical trials overseas for the treatment of SLE and active Cutaneous Lupus Erythematosus (CLE).

It is reported that SLE is a chronic systemic autoimmune disease characterized by multi-system damage symptoms, often leading to multi-organ and multi-system damage, posing a life-threatening condition. The pathogenesis of SLE is complex, including the proliferation and activation of autoreactive T cells and B cells, the production of various pathogenic autoantibodies, abnormal cytokine secretion, and receptor expression.

Studies have shown that TLR7 plays a central role in the pathogenesis of systemic lupus erythematosus (SLE). High expression of the TLR7 gene drives the production of autoantibodies in SLE, and gain-of-function mutations in TLR7 confer susceptibility to SLE. According to preclinical research data published at the 2023 American College of Rheumatology (ACR) meeting, DS-7011a has the ability to inhibit TLR7-stimulated production of inflammatory cytokines and showed no toxicity in monkeys after three months of treatment (including the maximum administered dose). These findings suggest that by targeting and inhibiting TLR7, DS-7011a holds promise as a potential therapeutic option for treating SLE.